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The binding of a humanized chimeric (cPiPP) recombi-
nant antibody (human IgG1, kappa linked to mouse 
variable regions) of high affinity (Ka 3 ´ 1010 M –1) and 
high specificity for human chorionic gonadotrophin 
(hCG) with MOLT-4 cells, an acute lymphoblastic 
leukaemia cell line derived from a patient in relapse, 
has been studied. The antibody binds on the membranes 
of the viable tumour cells as seen by flow cytometry. 
Biologically active pure hCG competes with the binding. 
No binding is seen with an irrelevant antibody di-
rected against an epitope on androgen indpendent 
prostate cancer cell line (DU145). Studies on perme-
abilized cells show that these cells synthesize both alpha 
and beta-hCG. Peripheral blood mononuclear cells of 
healthy individuals do not bind with cPiPP. The poten-
tial of this antibody for imaging a d selective delivery of 
radiations and/or drugs to tumour cells is suggested. 
 
Keywords: Chimeric anti-hCG antibody, ectopic expres-
sion of hCG, leukaemia cell line, membrane localization. 
 
RELAPSE after multidrug chemotherapy is a frequent oc-
currence in cancers. At this stage the tumour invariably 
spreads to other tissues, besides becoming resilient to primary 
chemotherapeutic drugs. Radiotherapy takes its own toll. 
Search has been going on for several years to develop strate-
gies for treatment of cancers at metastasis stage with ap-
proaches that could focus on the tumour cells without undue 
toxicity to other tissues. Amongst the emerging approaches 
are the use of antibodies directed at epitopes/markers 
primarily localized on cancer cells and completely absent 
or present at low concentrations on normal cells. 
 We report here the unexpected presence of human 
chorionic gonadotrophin (hCG) on membranes of a hu-
man T lymphoblastic leukaemia cell line derived from a 
patient in relapse, who had received prior multidrug chemo-
therapy. The cells from this patient were dev loped by ATCC 
as a cell line (CRL-1582) with the designation MOLT-4. 
MOLT-4 does not produce immunoglobulins nor has Ep-
stein-Barr virus. MOLT-4 cells have variable expression 
of various CD antigens [CD1 (49%), CD2 (35%), CD3 A 
(26%), CD3 B (33%), CD5(72%), CD6(22%) and 
CD7(77%)]. The interesting feature of the observation to 
e described here, is the presence of hCG on almost all 
c lls. The cells not only synthesize hCG, as is evident 
from studies on permeabilized cells, but also carry it on 
their membranes. An antibody of high specificity raised 
against the beta subunit of hCG has been humanized and 
expressed as a recombinant protein in plants1; it bind  to 
about 95% of the tumour cells. 
Materials and methods 
Cell cultures 
MOLT-4 cells (ATCC CRL-1582) wer grown in a hu-
midified incubator at 37°C under 5% CO2 and 95% air in 
RPMI1640 medium (Gibco) with 10% foetal calf serum 
(Hyclone) and antibiotic–antimycotic (penicillin 100mg/ml 
and streptomycin 0.25 g/ml; Gibco). The cells were subcul-
tured before they reached more then 70% confluency. A 
haemocytometer was used to count the cells and viability 
was determined by Trypan blue exclusion. An additional 
criterion employed for checking the viability was with 
pidium iodide (PI). 
Antibodies 
cPiPP is a chimeric ecombinant antibody engineered from 
a mouse monoclonal raised against beta-hCG2. The antibody 
is a recombinant protein having human IgG1 s constant 
heavy chain and human kappa as constant light chain fused 
with variable chains of mouse monoclonal antibody1. The 
antibody is expressed at high yield in tobacco leaves, as 
described previously3. It was purified by protein A affinity 
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Figure 1. Reactivity of (a) anti-alpha-hCG (P22376) and (b) anti-beta-hCG (cPiPP) antibodies to MOLT-4 cells. FACS analysis was carried out at 
antibody concentrations. In each case, 80–91% of cells show binding with these antibodies. Histogram 1 in both (a) and (b) shows fluorescence of 
cells without antibody. A non-hCG-reactive monoclonal antibody (MoAb 730) demonstrated a lack of recognition (Histogram 6 in (a)). 
 
 
chromatography. The association constant of the antibody 
for hCG is 3 ´  1010 M–1. The antibody is specific to hCG 
and does not recognize human TSH and human FSH both 
sharing the same alpha chain with hCG. It has < 5% cross 
reactivity with human LH2. 
 P22376 is a mouse monoclonal raised against alpha-hCG
4. 
It was purified by protein A affinity chromatography from 
ascites raised in syngenic Balb/c mice. 
 Monoclonal antibody 730 (MoAb 730) was raised against 
DU145 cells which are androgen independent prostate 
carcinoma5. This antibody was used as a negative control 
to rule out any non-specific binding of the anti-hCG anti-
bodies to the MOLT-4 cells. 
 A humanized chimeric antibody against LH-RH in which 
human IgG1, kappa is fused with mouse variable region, 
was employed as antibody isotype control for cPiPP.
Flow cytometry 
Fluorescene isothiocyanate (FITC) IgG1-labelled goat anti-
human IgG (Jackson Immuno Research) and phycoerythrin 
(PE)-labelled goat anti-mouse IgG (H + L) (Jackson Im-
muno Research) were used in flow cytometric analyses to 
detect the binding of cPiPP and P22376 respectively. 
 Two million cells were suspended in 1 ml FACS buffer 
(10 mM PBS, 1% BSA, 0.2% sodium azide) and 50 ml of 
the suspension was aliquoted per well per reaction, in a 96-
well round-bottom plate (Nunc). The cells were incubated 
with 2 mg cPiPP taken in 50ml FACS-buffer for 1h at 4°C. 
The cells were washed three times with FACS buffer, 
each time centrifuging at 500 g for 2 min at 4°C. FITC-
conjugated goat anti-human IgG at a dilution of 1 : 50 was 
used to detect the binding of cPiPP to MOLT-4 cells. For 
detectin of binding of the mouse monoclonal antibody 
P22376, PE-labelled goat anti-mouse IgG at 1
 : 50 dilution 
was used. For flow cytometric analysis, 5000 or 10,000 cells 
were analysed with BD LSR (Becton–Dickinson) instrument 
using WinMdi software (version 2.7). 
 Detection of intracellular synthesis of beta/alpha-hCG 
was done by flow cytometry using permeabilized cancer 
cells. For permeabilization, cells were incubated in chilled 
solution of methanol containing 0.01% Triton-X placed 
on ice for 1 min. After resu pension of cells in FACS 
buffer, staining was carried out as before. 
 Competition experiments with hCG (10,000 IU/mg) 
were conducted as follows: an aliquot of cPiPP was pre-
incubated with 10mg hCG for 1 h at 37°C. The binding 
capacity of the antibody was determined against a control 
in which the antibody was incubated under similar conditions 
with an equivalent volume of 10 mM Phosphate Buffer Saline 
(PBS). FACS analysis was undertaken to asses a decrease 
in cellular staining. 
Immunohistochemistry 
Two million cells were suspended in 1 ml FACS buffer 
(10 mM PBS, 1% BSA, 0.2% sodium azide ) and 50 ml of the 
suspension was aliquoted per well per reaction, in a 96-
well-round bottom plate (Nunc). The cells were permea-
bilized by incubating in chilled solution of methanol con-
taining 0.01% Triton-X placed on ice for 1 min. After 
resuspension, the cells were incubated with 2 mg cPiPP 
taken in 50 ml FACS buffer for 1 h at 4°C. The cells were 
washed three times with FACS buffer, each time centrifuging 
at 500 g for 2 min at 4°C. Horse Radish Peroxidase (HRP) 
conjugated goat anti-human IgG (Jackson Immuno Research) 
a b 
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Figure 2. Competition experiments with authentic hCG. cPiPP was preincubated with 10 mg of purified hCG and binding of the 
antibody with and without incubation with hCG was determined by flow cytometry. The number of cells binding with the antibody 
declined from (a) 90.77% to (b) 29.9% on scavenging of hCG-binding sites on the antibody by hCG. 
 
 
at a dilution of 1 : 400 was used as a second antibody to 
detect the binding of cPiPP to MOLT-4 cells and the cells 
were incubated in it for 1 h. After washing three times with 
FACS buffer, 2,4-diamino benzidine (DAB) was added as 
substrate followed by an incubation period of 15 min. The 
reaction was stopped by washing the cells with PBS. Cells 
were then examined under microscope for binding of the 
antibody. 
Results 
Figure 1 shows the binding of cPiPP and P22376 to the surface 
of MOLT-4 cells, as observed by FACS analyses. MOLT-4 
cells employed for FACS analyses were more than 95% 
viable as determined by Trypan blue exclusion and lack of 
PI uptake. A non-hCG reactive mouse monoclonal (MoAb 
730) differing in antigen binding regions and employed 
as a negative control demonstrated the lack of such binding 
with the tumour cells. As MoAb 730 is a monoclonal of 
mouse origin and shows lack of binding to MOLT-4 cells, 
it can be deduced that no nonspecific adhesion of the light 
and heavy chains takes place with the tumour cells. 
 In order to determine whether the binding of cPiPP was 
indeed to hCG exposed on the membranes of cells, com-
petition experiments with authentic purified hCG hormone 
were conducted. As shown in Figure 2, with the saturation 
of specific antigen-bi ding regions by hCG, lower binding 
capacity of the antibody was available for the hormone 
present on the membrane of tumour cells. Whereas at 
500 ng of antibody, 90% of MOLT-4 cells were binding 
the antibody, on competition with hCG, the specific antigen-
binding capacity of the antibody was diminished; and 
only 30% of the cells bound with the residual antibody. 
 Further evidence for cancer cells synthesizing both alpha-
and beta-hCG was obtained by intracellular staining of the 
cells with the two antibodies reacting specifically with al-
pha- and beta-hCG. The cells were permeabilized to enable 
the entry of alpha- and beta-hCG reactive antibodies into the 
cells, so that these could attach to the protein made by the 
cells and then be processed for FACS analysis. Figure 3 a
and b show clearly that majority of the cells were reactive 
with both the antibodies and binding appeared to be more 
than that observed on the membrane of cells. 
 In view of reports6 hat some cancer cells such as ChaGo 
(a non small cell lung cancer) express alpha-hCG and 
others express beta-hCG, it was of interest to determine 
whether diversity existed in the expression of either alpha- 
or beta-hCG in MOLT-4 cells. Double colour FACS 
an lyses of MOLT-4 cells was carried out, taking advantage 
of the fact that cPiPP has human Fc region and can be de-
tected by FITC-conjugated goat anti-human IgG, and 
P22376 being a mouse monoclonal, could be detected by 
PE-labelled goat nti-mouse IgG (Figure 4). We observed 
that more than 95% cells recognized both antibodies, i-
dicating the presence of both subunits on the same cell. 
 Further confirmation of the binding of cPiPP was ob-
tained by immunohistochemistry. MOLT-4 cells incubated 
with cPiPP bound with MOLT-4 cells as revealed by im-
muno-peroxidase staining (Figure 5 b). Incubation with 
nother chimeric humanized antibody against LH-RH 
(cLH-RH), which bears the same isotype as chimeric cPiPP 
f r heavy and light chain constant regions, was devoid of such 
binding (Figure 5 c). 
 In view of the observation that the cancerous cells of this 
T-cell lymphoblastic leukaemia carry hCG on their mem-
brane to which cPiPP binds, an obvious use of such antibody 
would be to employ it for imaging and delivery of radiations 
a b 
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Figure 3. Intracellular production of hCG by MOLT-4 cells. Open histograms in both (a) and (b) are controls. Filled histograms 
represent data obtained on incubation of permeabilized MOLT-4 with cPiPP (a) and P22376 (b). Permeabilized cells show 97% 
binding with (a) cPiPP and 99% with (b) P22376, indicating production of hCG within MOLT-4 cells. 
 
 
 
Figure 4. Dot-plot profiles of binding of anti-hCG antibodies to MOLT-4 cells. a, b, Fluorescence profile of cells incubated with (a) de ection 
antibody (anti-human FITC) alone and (b) anti-beta-hCG chimeric antibody (cPiPP) followed by incubation with detection antibody (anti-human 
FITC). More than 83% cells move in the lower right (LR) quadrant indicating binding with cPiPP compared to control. c, d, Fluorescence profile of 
cells incubated with (c) detection antibody (anti-mouse PE) alone and (d) anti-alpha-hCG antibody (P22376) followed by incubation with detection 
antibody (anti-mouse PE). More than 95% cells show binding to anti-alpha-hCG antibody compared to control, as shown in the upper left (UL) 
quadrant. e, Fluorescence profile of cells incubated with both cPiPP and P22376 followed by incubation with the two detection antibodies. About 95% 
of the cells bound with both these antibodies on the surface, as seen in the upper right (UR) quadrant of the profile, indicating that both the antibod-
ies recognize hCG present on the surface of the same cell. 
 
 
and drugs to the tumour cells. It was therefore necessary to 
determine whether this antibody discriminates between 
cancer cells and the normal healthy cells of the same 
lineage. Thus, binding of cPiPP with Peripheral Blood 
Mononuclear Cells (PBMC) of healthy normal people 
was investigated. cPiPP did not bind with PBMC, demon-
strating thereby the ability of cPiPP to bind selectively to 
cancer cells, sparing normal healthy leukocytes (Figure 6). 
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This experiment suggests the ability of cPiPP to distinguish 
between healthy and cancer cells for localizati n. 
Discussion 
hCG is primarily considered as a pregnancy hormone and its 
secretion in urine or blood is taken as a confirmed criterion  
 
 
 
 
 
 
 
 
Figure 5. Immunohistochemical localization of humanized chimeric 
antibody against beta-hCG (cPiPP) on MOLT-4 cells. a, Control with-
out cPiPP. b, With cPiPP. c, With humanized chimeric antibody against 
LH-RH, an isotype control. 
for diagnosis of pregnancy. Non-preg ant healthy women 
(and men) do not secrete this hormone in detectable amounts. 
Ectopic synthesis of alpha-, beta- or both subunits of hCG 
has been reported in lung cancer7,8, urothelial cancers9, 
colon adenocarcinoma10,11, pancreartic carcinoma12,13 liver 
malignancies, neuroendocrine tumours14 and in patients 
with poorly differentiated carcinomas15. Syrigos et al.16 
reported that 40% of pancreatic exocrine tumours produce 
beta-hCG and its production is correlated with adverse 
survival. The survival time for beta-hCG positive colorectal 
cancers was significantly shorter than beta-hCG negative 
cancer patients17. 
 The data communicated here show the synthesis of 
both alpha- and beta-hCG by MOLT-4, T-lymphoblastic 
leukaemia cells. While these are synthesized and ar  detect-
able intracellularly, their presence on membranes of tu-
mour cells is demonstrated by the binding of both anti-
alpha and anti-beta antibodies on the surface of live cells, 
as seen by flow cytometry. This implies that the hormo-
nal subunits are most likely in associated state, as hCG is 
secreted and picked up by receptors for this hormone on 
membranes of tumour cells. Over 90% of cells bind to 
cPiPP. The binding of monoclonal against alpha-hCG with 
the same cells is indicative of the receptor on these cells for 
the full native hormone, hCG. The binding is competed 
by highly purified biologically active hCG, and an irrelevant 
antibody such as the one directed at androgen-independent 
carcinoma cells does not bind with MOLT-4 cells. Further-
more, a chimeric antibody against an irrelevant antigen 
LH-RH does not bind with MOLT-4 cells as determined 
immunohistochemically (Figure 5 c), xcluding the possibility 
of non-specific attachment of human IgG1 and kappa with 
these cancer cells. Data in Figure 6 also cle rly show the 
lack of reactivity of cPiPP with PBMC isolated from healthy 
volunteers, thereby demonstrating the selective ability of this  
antibody to home to the tumour cells. This antibody may 
 
 
 
 
Figure 6. cPiPP antibody discriminates between canc r and normal 
peripheral blood mononuclear cells (PBMC) for binding. Migration 
profile of PBMC after incubation with cPiPP antibody. Profile of the 
cells overlapped the control PBMC not exposed to the antibody. 
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thus be useful for imaging and selective delivery of radia-
tions and/or drugs to such tumour cells without undue 
toxicity to normal healthy cells. The lack of cross-rea ti n 
of anti-hCG antibodies with normal tissues is also reflected 
by the multicentre phase I trials on a vaccine engendering 
anti-hCG antibodies18–20. Furthermore, the continuous pres-
ence of anti-hCG antibodies in circulation in sexually ac-
tive healthy women over two and a half years without any 
side effects, vouches for the long-term safety of anti-hCG 
antibodies21,22. Women had no obvious complaint or dis-
comfort, experienced normal ovulatory events and had 
regular menstrual cycles. The epitope against which 18–86% 
of total circulating antibodies of immunized women were 
directed overlaps with the epitope recognized by the chimeric
antibody used in these studies23. 
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